Prescrire Int. 2009 Feb;18(99):14.
Duloxetine in fibromyalgia: rejection. Marketing authorization rejected and rightly so.
[No authors listed]The European marketing authorization committee has ruled against the utilisation of duloxetine (Cymbalta) in the treatment of diffuse idiopathic polyalgic syndrome, alias fibromyalgia. A coherent position, given this psychotropic drug's unfavourable risk-benefit balance.
PMID: 19388210 [PubMed - indexed for MEDLINE]
